(2S,3S)-3-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-2-[3-[[(2S)-2-[[(2S)-2-amino-5-methylsulfanylpentanoyl]amino]heptadecanoyl]amino]propylamino]-3-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]propanoic acid | 1350817-25-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3S)-3-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-2-[3-[[(2S)-2-[[(2S)-2-amino-5-methylsulfanylpentanoyl]amino]heptadecanoyl]amino]propylamino]-3-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]propanoic acid
• CAS: 1350817-25-2
• 化学式: C₄₂H₇₅N₇O₁₃S
• 分子量: 918.163
• InChiKey: ZGSGAFNILYNYMA-MQHFXOOJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  63
• 可旋转键数：
  33
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  343
• 氢给体数：
  11
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  1-十四烯 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 盐酸 、 N-羟基丁二酰亚胺 、 palladium 10% on activated carbon 、 10% Pd(OH)₂ on C 、 水 、 氢气 、 三氧化硫吡啶 、 三乙酰氧基硼氢化钠 、 碳酸氢钠 、 1-羟基苯并三唑 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 145.0h， 生成 (2S,3S)-3-[(2S,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxyoxolan-2-yl]oxy-2-[3-[[(2S)-2-[[(2S)-2-amino-5-methylsulfanylpentanoyl]amino]heptadecanoyl]amino]propylamino]-3-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]propanoic acid
  参考文献：
  名称：

  Mechanistic Analysis of Muraymycin Analogues: A Guide to the Design of MraY Inhibitors

  摘要：

  The systematic structure activity relationship (SAX) of the muraymycins (MRYs) using an Ugi four-component reaction (U4CR) was investigated. The impact of the lipophilic substituent on antibacterial activity was significant, and the analogues 8 and 9 having a lipophilic side chain exhibited good activity against a range of Gram-positive bacterial pathogens, including MRSA and VRE. Further investigation of compounds 8 and 9 revealed these analogues to be selective inhibitors of the MraY transferase and nontoxic to HepG2 cells. The SAX of the accessory urea peptide moiety indicated that it could be simplified. Our SAX study of the MRYs suggests a probable mechanism for inhibition of the MraY, where the inner moiety of the urea dipeptide motif interacts with the carbohydrate recognition domain in the cytoplasmic loop S. The predicted binding model would provide further direction toward the design of potent MraY inhibitors. This study has set the stage for the generation of novel antibacterial "lead" compounds based on MRYs.

  DOI：

  10.1021/jm200906r

文献信息

• Mechanistic Analysis of Muraymycin Analogues: A Guide to the Design of MraY Inhibitors
  作者：Tetsuya Tanino、Bayan Al-Dabbagh、Dominique Mengin-Lecreulx、Ahmed Bouhss、Hiroshi Oyama、Satoshi Ichikawa、Akira Matsuda

  DOI：10.1021/jm200906r

  日期：2011.12.22

  The systematic structure activity relationship (SAX) of the muraymycins (MRYs) using an Ugi four-component reaction (U4CR) was investigated. The impact of the lipophilic substituent on antibacterial activity was significant, and the analogues 8 and 9 having a lipophilic side chain exhibited good activity against a range of Gram-positive bacterial pathogens, including MRSA and VRE. Further investigation of compounds 8 and 9 revealed these analogues to be selective inhibitors of the MraY transferase and nontoxic to HepG2 cells. The SAX of the accessory urea peptide moiety indicated that it could be simplified. Our SAX study of the MRYs suggests a probable mechanism for inhibition of the MraY, where the inner moiety of the urea dipeptide motif interacts with the carbohydrate recognition domain in the cytoplasmic loop S. The predicted binding model would provide further direction toward the design of potent MraY inhibitors. This study has set the stage for the generation of novel antibacterial "lead" compounds based on MRYs.